CARGO THERAPEUTICS INC (CRGX)
US14179K1016 - Common Stock
Top movers in Tuesday's pre-market session
Pre-market stock analysis on 2024-11-19: top gainers and losers in today's session.
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update...
CARGO Therapeutics to Participate in Upcoming Investor Conferences
CARGO Therapeutics to Participate in Upcoming Investor Conferences
CARGO Therapeutics to Participate in Upcoming Investor Conferences...
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma...
CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q2 2024
CRGX stock results show that Cargo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cargo Therapeutics (NASDAQ:CRGX) just reported results for the second quarter o...
Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week
Along with quarterly results, the clinical-stage company provided an encouraging business update.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update ...
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet...
CARGO Therapeutics is Now Oversold (CRGX)
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now
These are the breakout stocks to buy as they represent companies with stellar growth potential that are trading at attractive valuations.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
CARGO Therapeutics to Participate in Upcoming Investor Conferences
CARGO Therapeutics to Participate in Upcoming Investor Conferences...
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing...
CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q1 2024
CRGX stock results show that Cargo Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cargo Therapeutics (NASDAQ:CRGX) just reported results for the first quarter of...
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update ...
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) –
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell...
CRGX Stock Earnings: Cargo Therapeutics Misses EPS for Q4 2023
CRGX stock results show that Cargo Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
CRGX Stock Earnings: Cargo Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cargo Therapeutics (NASDAQ:CRGX) just reported results for the fourth quarter o...
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
CARGO Therapeutics today provided a business update and reported financial results for the quarter and year ending December 31, 2023....
CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference
CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference
CARGO Therapeutics announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston,...
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to...